Stemgenics is a Seattle-based company that specializes in disruptive nanotherapeutics technology, offering a multi-specific platform for therapeutic drug development. Their patent-protected non-integrating nanoparticles, known as NIMFA-NP, are designed to deliver a wide range of bioactive molecules into cells, tissues, organs, and organisms, making them highly effective in regenerative medicine, oncology, and vaccine development.
With a focus on regenerative medicine, Stemgenics' customizable NIMFA-NP can be functionalized with different bioactive molecules to target specific intracellular processes, allowing for tissue rejuvenation, organ revitalization, and lifespan extension. Additionally, their nanotechnology, protected by numerous patents, enables in vivo direct reprogramming of cells for liver and heart regeneration, as well as the treatment of neurodegenerative diseases and oncology through gene-specific mRNA and siRNA therapeutics.
Generated from the website